The loss of Sage Therapeutics under GAAP for 9 months of 2020 amounted to $368.822 million, which is 27.9% lower compared to $511.585 million in the previous year. Revenue increased 2.2% to $5.014 million, against $4.908 million a year earlier.
The loss of Sage Therapeutics under GAAP for 9 months of 2020 amounted to $368.822 million, which is 27.9% lower compared to $511.585 million in the previous year. Revenue increased 2.2% to $5.014 million, against $4.908 million a year earlier. 
investor.sagerx.com
English (US) 